v3.24.3

Stockholders' Equity (Details) |  |  |  |  |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended | 24 Months Ended |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Apr. 01, 2024 USD ($) | Mar. 26, 2024 USD ($) $ / shares shares | Dec. 07, 2023 USD ($) $ / shares shares | Nov. 29, 2023 shares | Aug. 11, 2023 USD ($) $ / shares shares | Dec. 09, 2022 USD ($) shares | Dec. 06, 2022 shares | Oct. 07, 2022 shares | Sep. 19, 2022 USD ($) shares | May 10, 2022 USD ($) shares | Nov. 01, 2021 $ / shares shares | Aug. 31, 2024 USD ($) shares | Sep. 16, 2024 shares | Jun. 30, 2024 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) $ / shares shares | Jun. 30, 2024 USD ($) $ / shares shares | Aug. 04, 2023 $ / shares shares | Aug. 03, 2023 $ / shares | Jul. 19, 2022 shares | May 09, 2022 $ / shares shares | Nov. 25, 2020 USD ($)
Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares authorized |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 1,000,000 | 1,000,000 |  |  |  |  |
Preferred stock, par value | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 | $ 0.001 | $ 0.001 |  |  |  |  |
Preferred stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |
Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares authorized |  |  |  |  |  |  |  |  |  |  |  |  |  | 275,000,000 | 275,000,000 | 275,000,000 |  |  |  |  |
Reverse Stock Split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Pre-split shares required for one post-split share of common stock |  |  |  |  |  |  |  | 25 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.11 | $ 12.20 | $ 2.11 |  |  |  |  |
Subscription receivable | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 204,000 |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of warrants | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,464,000 |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2.11 | $ 12.20 | $ 2.11 |  |  |  |  |
Subsequent Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of warrants | $ |  |  |  |  |  |  |  |  |  |  |  | $ 4,000 |  |  |  |  |  |  |  |  |
Restricted Stock Units |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares vested |  |  |  |  |  |  |  |  |  |  |  |  |  | 42,054 | 10,878 |  |  |  |  |  |
Restricted Stock Units | Subsequent Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares vested |  |  |  |  |  |  |  |  |  |  |  |  | 12,210 |  |  |  |  |  |  |  |
Employee Stock Option |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |  |  |
Series 2022 Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares authorized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 |
Preferred stock, par value | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |
Preferred stock, conversion ratio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
Preferred stock, shares issued |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |  |
Preferred stock, proceeds from issuance | $ |  |  |  |  |  |  |  |  |  | $ 270 |  |  |  |  |  |  |  |  |  |  |
Common shares issued upon conversion of preferred stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 40 |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |  |
Preferred stock, proceeds from issuance | $ |  |  |  |  |  |  |  |  |  | $ 270 |  |  |  |  |  |  |  |  |  |  |
Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reverse Stock Split |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reverse stock split, shares received per share tendered |  |  |  | 0.05 |  |  |  | 0.04 |  |  |  |  |  |  |  |  |  |  |  |  |
Pre-split shares required for one post-split share of common stock |  |  |  | 20 |  |  |  | 25 |  |  |  |  |  |  |  |  |  |  |  |  |
Fractional shares issued in reverse stock split |  |  |  | 0 |  |  |  | 0 |  |  |  |  |  |  |  |  |  |  |  |  |
RubrYc Therapeutics | Series A-2 Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued |  |  |  |  |  |  |  |  | 5,117 |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, proceeds from issuance | $ |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, shares issued |  |  |  |  |  |  |  |  | 5,117 |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock, proceeds from issuance | $ |  |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Cantor Fitzgerald Underwriting | At-The-Market Offerings | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 170,989 | 289,144 |  |  |  |  |  |
Common stock, net proceeds from issuance | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,700,000 | $ 6,400,000 |  |  |  |  |  |
Subscription receivable | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 204,000 |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 170,989 | 289,144 |  |  |  |  |  |
Cantor Fitzgerald Underwriting | At-The-Market Offerings | Common Stock | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate offering price | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000,000
Wainwright Underwriting | At-The-Market Offerings |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, proceeds from issuance | $ |  |  |  |  |  | $ 2,864,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agent fee percentage |  |  |  |  |  | 7.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | At-The-Market Offerings | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  | 76,538 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  | 76,538 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | At-The-Market Offerings | Common Stock | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 91,730 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 91,730 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | At-The-Market Offerings | Common Stock | Series A warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 168,267 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 168,267 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | At-The-Market Offerings | Common Stock | Series B warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 168,267 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  | 168,267 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Underwriters purchase option period |  |  |  |  |  | 30 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 50,480 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 50,480 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Representative Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 10,094 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional shares for purchase, percentage of aggregate shares in offerings |  |  |  |  |  | 6.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 10,094 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Series A warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Wainwright Underwriting | H.C. Wainwright & Co. | Underwriters Option | Common Stock | Series B warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  | 25,240 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate offering price | $ |  |  |  |  | $ 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 202,595 |  |  |  |  |  |  |
Common stock, gross proceeds from issuance | $ |  |  |  |  | $ 5,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, net proceeds from issuance | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  |  |  |  |
Common stock, shares available for future issuance |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |
Term of stock purchase agreement |  |  |  |  | 24 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial commitment shares issued |  |  |  |  | 10,573 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional commitment shares issued |  |  |  |  | 10,573 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 202,595 |  |  |  |  |  |  |
Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate offering price | $ |  |  |  |  | $ 10,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares available for purchase when stock price closes between $3 and $20 per share |  |  |  |  | 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares available for purchase when stock price closes between $20 and $40 per share |  |  |  |  | 7,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares available for purchase when stock price closes at or above $40 per share |  |  |  |  | 10,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of common stock purchased in single transaction | $ |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Lincoln Park Stock Purchase Agreement | At-The-Market Offerings | Common Stock | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock price permitting the sale of up to 5,000 shares | $ / shares |  |  |  |  | $ 3.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock price permitting the sale of up to 7,500 shares | $ / shares |  |  |  |  | 20.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock price permitting the sale of up to 10,000 shares | $ / shares |  |  |  |  | 40.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stock price permitting accelerated purchase clause | $ / shares |  |  |  |  | $ 4.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of "additional accelerated purchases" that may be directed |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Private placement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, gross proceeds from issuance | $ |  | $ 15,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, net proceeds from issuance | $ |  | $ 14,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduced placement agent fee percentage |  | 4.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Private placement | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  | 2,585,963 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  | 2,585,963 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Private placement | Series E Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  | 5,287,278 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 2.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 2.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  | 5,287,278 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Private placement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, net proceeds from issuance | $ |  |  | $ 4,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accrued stock issuance costs | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 369,000 |  | $ 369,000 |  |  |  |  |
Securities Purchase Agreement | Alliance Global Partners | Private placement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement for legal expenses | $ |  |  | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Non-accountable expense allowance | $ |  |  | $ 15,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agent fee percentage |  |  | 5.50% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Series C Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement | Alliance Global Partners | Private placement | Common Stock | Series D Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reimbursement for legal expenses | $ | $ 50,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Agent fee percentage | 6.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reduced placement agent fee percentage | 4.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  | 2,701,315 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, gross proceeds from issuance | $ |  | $ 15,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, net proceeds from issuance | $ | $ 14,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  | 2,701,315 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  | 2,585,963 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  | 2,585,963 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Series E Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  | 5,287,278 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 2.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  | 5,287,278 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  | $ 2.64 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Common Shares and Series E Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  | $ 2.85 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  | 2.85 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  | $ 2.849 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Term of 2024 Securities Purchase Agreement |  | 1 year |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Failure to file registration statement, delinquency period |  | 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase agreement exclusivity period |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  | $ 2.849 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise, common stock ownership limitation |  | 4.99% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise, common stock ownership limitation (at the election of the holder) |  | 9.99% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of days to file a registration statement |  | 75 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of days to file a registration statement (in the event of a "full review" by SEC) |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Suspension period |  | 15 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Partial liquidated damages, percent of aggregate security subscriptions |  | 6.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Securities Purchase Agreement and Warrants | Private placement | Common Stock | Pre-funded and Series E Warrants | Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant holder's election, period of written notice |  | 61 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of days to file a registration statement |  | 60 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Partial liquidated damages, percent of aggregate security subscriptions |  | 1.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants | H.C. Wainwright & Co. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of warrants | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,207,000 |  |  |  |  |  |
Warrants | H.C. Wainwright & Co. | Common Stock | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.001 |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.001 |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  | 0 |  |  |  |  |
Warrants | H.C. Wainwright & Co. | Common Stock | Representative Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 26.00 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 26.00 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Warrants | H.C. Wainwright & Co. | Common Stock | Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10.00 | $ 20.80 |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10.00 | 20.80 |  |  |
Warrants | H.C. Wainwright & Co. | Common Stock | Series A warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 173,795 |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20.80 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20.80 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 17,064 |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 173,795 |  |  |  |
Warrants | H.C. Wainwright & Co. | Common Stock | Series B warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 102,900 |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20.80 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20.80 |  |  |
Warrants, exercisable term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 89,059 |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 102,900 |  |  |  |
Warrants | Bryan Capital | Common Stock | Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  |  |  |  |  | 2,579 |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  | $ 665 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  |  |  |  |  |  |  |  |  | 2,579 |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  |  |  |  |  |  |  |  |  | $ 665 |  |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock, shares issued |  |  | 600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Pre-Funded Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  | $ 1.9999 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 0.0001 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,650,000 |  | 1,650,000 |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 1,650,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Combined price per share of common stock and warrants | $ / shares |  |  | $ 1.9999 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of warrants | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,464,000 |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Warrants | Subsequent Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from exercise of warrants | $ |  |  |  |  |  |  |  |  |  |  |  | $ 4,000 |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Series C Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,178,500 |  | 1,178,500 |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Series C Warrants | Subsequent Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Series D Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuances of Common Stock |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares issued |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercise price | $ / shares |  |  | $ 2.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, exercisable term |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,053,500 |  | 1,053,500 |  |  |  |  |
Warrants, shares of common stock issued upon conversion |  |  | 2,250,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants | Alliance Global Partners | Private placement | Common Stock | Series D Warrants | Subsequent Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants, shares exercised |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |

X
- Definition Amount accrued for stock issuance costs incurred and payable to the sales agent. + References No definition available. + Details
Name: | ibio_AccruedStockIssuanceCosts
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate amount of proceeds from sales of common stock authorized through the medium of an investment bank, pursuant to an equity offering agreement. + References No definition available. + Details
Name: | ibio_AggregateOfferingPriceInStockSalesAgreement
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum fair value of common stock shares that may be purchased in a single transaction, pursuant to the terms of the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_CommonStockMaximumFairValueOfSharesPurchasedPerTransaction
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $3.00 per share, but less than $20.00 per share. + References No definition available. + Details
Name: | ibio_CommonStockMaximumSharesDirectedForPurchase1
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $20.00 per share, but less than $40.00 per share. + References No definition available. + Details
Name: | ibio_CommonStockMaximumSharesDirectedForPurchase2
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of common stock shares the Company may, at any time, direct the counterparty of the stock purchasing agreement to purchase at a price per share determined in the stock purchasing agreement, provided that the closing share price on the NYSE is equal to or greater than $40.00 per share. + References No definition available. + Details
Name: | ibio_CommonStockMaximumSharesDirectedForPurchase3
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of common stock shares the Company issued to Lincoln Park as "additional commitment shares" as consideration for participation in the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_CommonStockSharesIssuedAdditionalCommitmentShares
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of common stock shares the Company issued to Lincoln Park as "initial commitment shares" as consideration for participation in the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_CommonStockSharesIssuedInitialCommitmentShares
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants. + References No definition available. + Details
Name: | ibio_DaysToFileRegistrationStatement
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition In the event of a "full review" by the SEC, the maximum number of days following the filing date of the 2024 Securities Purchase Agreement the Company has agreed to prepare and file a registration statement with the Securities and Exchange Commission registering the resale of the shares of Common Stock issued to the Securities Purchasers in the Private Placement and the shares underlying the 2024 Pre-Funded Warrants and the Series E Warrants. + References No definition available. + Details
Name: | ibio_DaysToFileRegistrationStatementSecReview
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of days in which the Company may suspend the 2024 Securities Purchase Agreement inside the one year period without being in breach. + References No definition available. + Details
Name: | ibio_DaysToSuspendSecuritiesPurchasingAgreement
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Duration of the 2024 Securities Purchase Agreement. + References No definition available. + Details
Name: | ibio_DurationOfSecuritiesPurchasingAgreement
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for cost incurred for a non-accountable expense allowance granted to the sales agent. + References No definition available. + Details
Name: | ibio_NonAccountableExpenseAllowanceGrantedToSalesAgent
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The number of "additional share purchases" the Company may exercise when certain conditions in the stock purchasing agreement permit. + References No definition available. + Details
Name: | ibio_NumberOfAdditionalAcceleratedSharePurchases
Namespace Prefix: | ibio_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares an equity holder will tender in order to receive one share of the Company's common stock share following the conversion of a reverse stock split. + References No definition available. + Details
Name: | ibio_NumberOfSharesTenderedInReverseStockSplit
Namespace Prefix: | ibio_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The effective ownership of the outstanding shares of the Company's common stock immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed. + References No definition available. + Details
Name: | ibio_OwnershipThresholdPercentage
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The effective ownership of the outstanding shares of the Company's common stock, with written notice given by the holder to the Company, immediately after exercise of warrants - threshold percentage for which warrant holders may not exceed. + References No definition available. + Details
Name: | ibio_OwnershipThresholdPercentageElectionOfHolder
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition In the event that a resale registration statement is not filed or declared effective, the percentage multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, as partial liquidated damages. + References No definition available. + Details
Name: | ibio_PartialLiquidatedDamagesPenaltyPercentageOnAggregateSubscriptionsBySecurityPurchaser
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum amount of additional shares available for purchase by underwriters through the issuance of warrants, expressed as a percentage of the aggregate number of shares of common stock and pre-funded warrants currently included in equity offerings. + References No definition available. + Details
Name: | ibio_PercentageOfTotalCommonSharesInOfferingWarrantsAvailableForUnderwriters
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reduced placement agent fees for certain investors paid in cash, represented as a percentage of aggregate gross proceeds. + References No definition available. + Details
Name: | ibio_ReducedPlacementAgentFeesPaidAsPercentageOfAggregateGrossProceeds
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition In the event that the resale registration statement is not (i) filed by the Filing Date or (ii) declared effective by the SEC by the Effectiveness Date, then, in addition to any other rights the Securities Purchasers may have under the 2024 Securities Purchase Agreement or under applicable law, on the Filing Date or the Effectiveness Date for a maximum of six months (each such date being referred to herein as an "Event Date") and on each monthly anniversary of such Event Date (if the resale registration statement shall not have been filed or declared effective by the applicable Event Date) until the resale registration statement is filed or declared effective, the Company shall pay to each Securities Purchaser an amount in cash, as partial liquidated damages and not as a penalty, equal to the product of 1.0% multiplied by the aggregate subscription amount paid by such Securities Purchaser pursuant to the 2024 Securities Purchase Agreement for each security not registered, which amount shall be capped at 6%. + References No definition available. + Details
Name: | ibio_RegistrationStatementDelinquencyPeriod
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow for cost incurred directly with the issuance of an equity security for the reimbursement of legal expenses incurred by the sales agent. + References No definition available. + Details
Name: | ibio_StockIssuanceCostsLegalExpenseReimbursement
Namespace Prefix: | ibio_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Pursuant to the 2024 Stock Purchase Agreement, the period for which the Company is prohibited from entering into any agreement to issue or announce the issuance/proposed issuance of any shares of common stock or convertible securities. + References No definition available. + Details
Name: | ibio_StockPurchaseAgreementExclusivityPeriod
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 5,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_StrikePriceToDirectPurchaseOfStock1
Namespace Prefix: | ibio_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 7,500 shares of the Company's common stock at a price per share determined in the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_StrikePriceToDirectPurchaseOfStock2
Namespace Prefix: | ibio_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase up to 10,000 shares of the Company's common stock at a price per share determined in the stock purchasing agreement. + References No definition available. + Details
Name: | ibio_StrikePriceToDirectPurchaseOfStock3
Namespace Prefix: | ibio_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The closing price of the Company's common stock on the NYSE, when equal to or greater than, that permits the Company to direct the counterparty in the stock purchasing agreement to purchase the maximum allowable amount of the Company's common stock at a price per share determined in the stock purchasing agreement. Additionally, the counterparty may be directed to purchase additional shares of the Company's common stock in an "accelerated purchase," and one or more "additional accelerated purchases" on the business day immediately following the initial purchase of shares. + References No definition available. + Details
Name: | ibio_StrikePriceToDirectPurchaseOfStock4
Namespace Prefix: | ibio_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of a stock purchase agreement. + References No definition available. + Details
Name: | ibio_TermOfPurchaseAgreement
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Threshold number of days following the close of an at-the-market equity offering for the underwriters of the offering to exercise their option to purchase additional shares/warrants pursuant to an Underwriting Agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | ibio_UnderwritersPurchaseOptionPeriod
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Underwriting fee paid to agent for the sale of stock, expressed as a percentage of gross proceeds received. + References No definition available. + Details
Name: | ibio_UnderwritingDiscountFeePercentage
Namespace Prefix: | ibio_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum days of prior written notice needed to satisfy the holder's election to exercise warrants that give the holder, together with affiliates, a beneficial ownership in the Company's common stock of not more than 9.99%. + References No definition available. + Details
Name: | ibio_WarrantExercisesOwnershipLimitationTermOfWrittenNotice
Namespace Prefix: | ibio_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | srt_ShareRepurchaseProgramAbstract
Namespace Prefix: | srt_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ClassOfStockDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of subscription receivable from investors who have been allocated common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details
Name: | us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The maximum number of common shares permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details
Name: | us-gaap_CommonStockSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued for each share of convertible preferred stock that is converted. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16 + Details
Name: | us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of warrants issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of common shares issuable upon conversion for each share of preferred stock to be converted. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockConvertibleConversionRatio
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockParOrStatedValuePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details
Name: | us-gaap_PreferredStockSharesAuthorized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details
Name: | us-gaap_PreferredStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from holders exercising their stock warrants. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromWarrantExercises
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Cash received on stock transaction after deduction of issuance costs. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor. + References No definition available. + Details
Name: | us-gaap_SaleOfStockConsiderationReceivedPerTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The number of shares issued or sold by the subsidiary or equity method investee per stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of a stock split. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockSplits
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4 + Details
Name: | us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:pureItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_WarrantsAndRightsNoteDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_CantorFitzgeraldUnderwritingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_WainwrightUnderwritingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_HcWainwrightAndCompanyLlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_LincolnParkStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_SecuritiesPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesEWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_AllianceGlobalPartnersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesCWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesDWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_SecuritiesPurchaseStockAndWarrantsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_CommonStockAndSeriesEWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsAndSeriesEWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ibio_WarrantAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=ibio_CommonStockWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ibio_BryanCapitalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |